Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to give informed consent and are willing to follow all study procedures
- Adults aged 18 or older, of any gender or race
- People who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or a related blood cancer condition called MDS/MPN
- People who do not have a fully matched donor and have received a "half-matched" (haploidentical) stem cell transplant, with a specific combination of anti-rejection medications (Cyclophosphamide, Cyclosporine A, and Mycophenolate mofetil) given on particular days after the transplant
- People who received their half-matched stem cell transplant after a conditioning treatment (a course of therapy to prepare the body for transplant), using either bone marrow or blood stem cells as the graft
- Women who could become pregnant must have a negative pregnancy test within 8 days before starting the study treatment
- Women who could become pregnant, and men whose partners could become pregnant, must agree to use a highly effective form of contraception from the time of giving consent until at least 52 weeks after the last dose of study treatment
Who may not be able to join:
- People under 18 years of age
- People with an active infection that is not under control
- People whose AML has spread to the central nervous system (brain and spinal cord)
- People with a low physical functioning score (below 60% on a standard medical scale) or serious organ problems, including weakened heart function, reduced lung capacity, or poor kidney function (confirm with trial site)
- People who are pregnant, breastfeeding, or planning to become pregnant during the study
- People whose cancer comes back rapidly before day 30 after their stem cell transplant
- People who develop a serious immune reaction called acute Graft-versus-Host Disease (GvHD) before day 30 after their stem cell transplant
- People who have had a second allogeneic (donor) stem cell transplant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +39 02 8224 5157
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Graft-versus-host disease-free and progression-free survival (GPFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.